Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a research note issued to investors on Thursday morning.

Several other brokerages have also commented on ABEO. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th.

Abeona Therapeutics Stock Down 0.3 %

Shares of NASDAQ ABEO opened at $6.39 on Thursday. The stock has a 50 day moving average price of $6.26 and a 200 day moving average price of $5.35. The firm has a market capitalization of $277.77 million, a price-to-earnings ratio of -2.38 and a beta of 1.52. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently modified their holdings of ABEO. Geode Capital Management LLC lifted its position in Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after acquiring an additional 83,050 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Abeona Therapeutics during the third quarter valued at $160,000. Jane Street Group LLC acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at $84,000. Western Standard LLC raised its stake in Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after acquiring an additional 110,998 shares during the last quarter. Finally, Citigroup Inc. lifted its position in Abeona Therapeutics by 10.1% during the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after acquiring an additional 56,332 shares during the period. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.